Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

Inclusion Criteria:

• Documentation of IgAN diagnosis established on kidney biopsy obtained any time priorto or during the Screening Period for participants with eGFR ≥ 30 mL/min/1.73 m^2.

• For participants in the AdKD cohorts, eGFR 20 to 29 mL/min/1.73 m2 a kidney biopsyis required within 6 months prior to Screening or during the Screening Period.

• UPCR ≥ 0.75 g/g or UP ≥1 g/day calculated from the mean of two 24-hour urine duringthe Screening Period.

• Estimated GFR ≥ 30 mL/min/1.73 m2 at Screening.

• Stable and maximum allowed or tolerated RASI (ACEI and/or ARB) dose for ≥ 3 monthsprior to Screening with no planned change during Screening through Week 106.

• Participants who are receiving SGLT2I, DEARA, MRA or ERA must be on a stable andmaximum allowed or tolerated dose for ≥ 3 months prior to Screening with no plannedchange in dose through Week 106.

Exclusion Criteria:

• Diagnosis of rapid progressive glomerulonephritis as measured by eGFR loss ≥ 50%over a period of 3 months prior to Screening.

• Secondary IgAN (eg, due to systemic lupus erythematosus (SLE), cirrhosis, or celiacdisease; IgAV-N may be eligible).

• Concomitant clinically significant renal disease other than IgAN.

• Prior use of immunosuppressive treatment within 3 months of screening.

• Uncontrolled diabetes mellitus with glycosylated hemoglobin (HbA1c) > 8.5%.

• Henoch-Schonlein purpura (IgAV) requiring systemic immunosuppressive therapy within 12 months of Screening.

• History of kidney transplant or planned kidney transplant during the TreatmentPeriod.

• Splenectomy or functional asplenia.

• History of Neisseria meningitidis infection.

• Active systemic bacterial, viral, or fungal infection within 14 days prior torandomization.